These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7751425)

  • 21. Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis.
    Brown RE; Kendall MJ; Halpern MT
    J Clin Pharm Ther; 1997 Feb; 22(1):67-76. PubMed ID: 9292406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers.
    Sawicki W; Deptulski T; Janicki S
    Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
    Laufen H; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
    Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
    Gunasekara NS; Noble S
    Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state.
    Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF
    Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.
    Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Härkönen R
    Drugs; 1987; 33 Suppl 4():118-21. PubMed ID: 2887419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
    Halkin H; Almog S; Friedman E
    Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms].
    Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G
    Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.